View Report Details. Global Intravascular Ultrasound Market

Size: px
Start display at page:

Download "View Report Details. Global Intravascular Ultrasound Market"

Transcription

1 View Report Details Global Intravascular Ultrasound Market

2 View Report Details Executive Summary Intravascular Ultrasound, one of the fastest growing segments of interventional cardiology, is a diagnostic tool that is used to determine the structure of an artery segment. It uses a small ultrasound transducer, located at the end of a catheter that can be advanced into a coronary artery. By utilizing IVUS in the cardiac catheterization laboratory, physicians are able to determine the structure of artery. IVUS is commonly done to make sure a stent is correctly placed during angioplasty. The present report offers a comprehensive analysis of the worldwide IVUS market with focus on regional markets like Japan, the United States and Europe. The largest IVUS market is Japan where reimbursement criteria is flexible and also has high PCI procedures which plays an important role in IVUS market. The second largest market is the United States followed by Europe. Major IVUS companies are increasingly setting their sights on emerging Asian markets due to increasing healthcare awareness among people and rising consumer income. The competition in the global IVUS market is intense with few large players viz. Volcano Corporation, Boston Scientific Corporation and Terumo Corporation. The competitive landscape of the global and regional IVUS markets, along with the company profiles of the leading players are discussed in detail. The developments observed within the industry include launch of spectra spinal cord stimulator system, introduction of Rubicon support catheter and emergence of PTCA Balloon Dilatation Catheter. However, the industry remains threatened by certain challenges which include lack of reimbursement, possible threat from OCT procedures and stringent regulations. The major factors which will contribute in the growth of the industry include rising ageing population, low penetration into PCI procedures, increasing PCI and stent procedures, rising healthcare expenditure and rising global GNI. By combining SPSS Inc. s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

3 IVUS is a medical imaging technique which uses a specially designed catheter with a miniaturized ultrasound probe attached to the distal end of the catheter.. Global IVUS Market ( E) The global IVUS market increased from US$... million in 2010 to US$... million in 2011 showing a growth of %. In 2012, the global IVUS market was estimated to have increased to US$... million showing an improvement of..%. In 2012, Japan was estimated to represent the largest regional market for intravascular ultrasound worldwide with a share of.% followed by the US and Europe which accounted for..% and..% respectively. Market Growth Drivers: Global IVUS Procedures Share by Region (2012E) -Increasing Aging Population -Low Penetration into PCI Procedures - Increasing PCI and Stent Procedures -Ease of Use by Integration of Technology -Rising Healthcare Expenditure -Increasing Global GNI (Gross National Income) Industry Developments and trends: -Launch of Precision Spectra Spinal Cord Stimulator System -Introduction of Rubicon Support Catheter -Launch of Emerge PTCA Balloon Dilatation Catheter -Introduction of Victory Guide wire for Crossing Resistant Lesions in Peripheral Arteries Challenges -Lack of Reimbursement -Possible Threat from OCT Procedures -Stringent Regulations Japan US Europe Others

4 The IVUS is used during the percutaneous coronary intervention (PCI) / percutaneous trans luminal coronary angioplasty (PTCA) procedure.. Japanese IVUS Market ( E) The IVUS market in Japan increased from US$... million in 2010 to US$... million in 2011 showing an improvement of %. In 2012, the market was estimated to have declined to US$... million, a decrease of..%. In 2012, the IVUS penetration in Japan was estimated to be..%. In 2011, the IVUS market in the US increased from US$... million in 2010 to US$... million in 2011 showing a growth of %. As of 2012, the market was estimated to have reached US$... million showing a rise of.% in comparison with In 2012, the IVUS penetration in the US was estimated to be..%. As of 2011, the European IVUS market rose by % increasing from US$... million in 2010 to US$... million in The market was estimated to have reached US$... million in 2012 showing an improvement of.% in comparison with In 2012, the IVUS penetration in Europe was estimated to be %. US IVUS Market ( E) European IVUS Market ( E)

5 The Global IVUS Market is highly fragmented and companies face intense competition. In 2012, the market leader was Volcano... IVUS Market in Rest of the World ( E) Global IVUS Market Forecast ( F) F 2013F 2014F 2015F The IVUS market in rest of the world declined from US$... million in 2010 to US$$...million in 2011 showing a decrease of %. In 2012, the market was estimated to have witnessed an increase of..% by reaching to US$... million in comparison with On the competition front, Volcano Corporation was the leading company in the IVUS market in the US, Europe and Japan, with approximately %, % and % of the market share for the year 2012, followed by Boston Scientific. The global IVUS market increased from US$... million in 2010 to US$... million in 2011 showing a growth of.%. The global IVUS market is expected to reach US$... million in Global IVUS market is expected to grow at a CAGR of..% for the period spanning Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa

6 Table of Contents 1. Overview 2. Global IVUS Market -Regional Breakdown 3. Regional Analysis 3.1 Japan -Penetration Rate -PCI Procedures 3.2 The US -Penetration Rate -PCI Procedures 3.3 Europe -Penetration Rate -PCI Procedures 3.4 Rest of the World -PCI Procedures 4. Market Dynamics 4.1 Growth Drivers Increasing Aging Population Low Penetration into PCI Procedures Increasing PCI and Stent Procedures Ease of Use by Integration of Technology Rising Healthcare Expenditure Increasing Global GNI (Gross National Income) List of Graphs & Tables List of Charts Outline for IVUS usage in PCI Global IVUS Market ( E) Global IVUS Procedures-Share by Regions (2012E) Japanese IVUS Market ( E) PCI Procedures in Japan ( E) IVUS Penetration into PCI Population in Japan ( E) Functional PCI Utilization ( E) US IVUS Market ( E) PCI Procedures in the US ( E) IVUS Penetration into PCI Population in the US ( E) European IVUS Market ( E) PCI Procedures in Europe ( E) IVUS Penetration into PCI Population in Europe ( E) IVUS Market in Rest of the World ( E) PCI Procedures in Rest of the World ( E) Ageing Population Worldwide, age>65 ( ) IVUS Penetration into PCI Procedures Worldwide ( E) Global PCI Procedures ( E) Global Stent Market Growth ( E) Healthcare Expenditure Worldwide ( E) World Gross National Income ( ) US IVUS Market-Share by Companies (2012) Japanese IVUS Market-Share by Companies (2012) European IVUS Market-Share by Companies (2012) Volcano Corporation Revenue by Segment (2012) Volcano Corporation Revenue by Region (2012) Volcano Corporation Revenue ( ) Boston Scientific Sales by Product Categories (2012) Boston Scientific Sales by Region (2012) Boston Scientific-Total Sales and Net Income ( ) Terumo Corporation Sales by Product Categories (FY2011) Terumo Corporation Sales by Region (FY2011) Terumo Corporation-Total Sales and Net Income (FY2007-FY2011) Global IVUS Market Forecast ( F)

7 -Embarkations by Port 4.2 Developments Launch of Precision Spectra Spinal Cord Stimulator System Introduction of Rubicon Support Catheter Launch of Emerge PTCA Balloon Dilatation Catheter Introduction of Victory Guide wire for Crossing Resistant Lesions in Peripheral Arteries List of Tables Use of IVUS Pre- and Post-PCI Comparison of traditional and integrated IVUS system Physical Properties of OCT vs. IVUS Image characteristics of OCT vs. IVUS Dependent & Independent Variables ( ) Correlation Matrix Model Summary Coefficient of Determination Regression Coefficients Output 4.3 Challenges Lack of Reimbursement Possible Threat from OCT Procedures Stringent Regulations 5. Competitive Landscape 5.1 The US 5.2 Japan 5.3 EMEA 6. Company Profiles 6.1 Volcano Corporation Business Overview Financial Highlights Business Strategies -Product Innovation -Growth through Acquisitions 6.2 Boston Scientific Corporation Business Overview Financial Highlights Business Strategies -Growth through Market Expansion -Focus on Innovation

8 6.3 Terumo Corporation Business Overview Financial Highlights Business Strategies -New Product Development -Strategic Acquisitions 7. Market Outlook 7.1 Market Forecast 7.2 Forecast Methodology Dependent and Independent Variables Correlation Analysis Regression Analysis

9 Contact Us: View Report Details These are abridged and sanitized sample pages from the comprehensive report on the Global Intravascular Ultrasound (IVUS) Market. To know more about this report or for any customized research requirement, please contact the following: Vikas Gupta BD Manager Koncept Analytics CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P T C:

Global Contract Catering Market: Industry Analysis & Outlook ( )

Global Contract Catering Market: Industry Analysis & Outlook ( ) Industry Research by Koncept Analytics Global Contract Catering Market: Industry Analysis & Outlook ------------------------------------ (2016-2020) December 2016 1 Executive Summary The term foodservice

More information

Patient Handling Equipment Market (Europe & North America): Industry Analysis & Outlook ( )

Patient Handling Equipment Market (Europe & North America): Industry Analysis & Outlook ( ) Industry Research by Koncept Analytics Patient Handling Equipment Market (Europe & North America): Industry Analysis & Outlook ----------------------------------------- (2018-2022) July 2018 1 Executive

More information

Financial Results for the First Half of. the Fiscal Year Ending March 31, 2014 (FY2013) Terumo Corporation November 6, 2013

Financial Results for the First Half of. the Fiscal Year Ending March 31, 2014 (FY2013) Terumo Corporation November 6, 2013 Financial Results for the First Half of the Fiscal Year Ending March 31, 2014 (FY2013) Terumo Corporation November 6, 2013 Highlights in 1H Corporate Cardiac & Vascular Blood Management General Hospital

More information

TERUMO CORPORATION. Financial Results for FYE/Mar April 30 th, 2008

TERUMO CORPORATION. Financial Results for FYE/Mar April 30 th, 2008 TERUMO CORPORATION Financial Results for FYE/Mar.2008 April 30 th, 2008 1 I. Financial Results for FYE/Mar.2008 II. Review of STeP UP (FY05-07) III. New mid-term business plan (FY08-10) 2 3 Financial Results

More information

1st Quarter Financial Results for FYE/Mar Terumo Corporation July 30, 2009

1st Quarter Financial Results for FYE/Mar Terumo Corporation July 30, 2009 1st Quarter Financial Results for FYE/Mar 2010 Terumo Corporation July 30, 2009 1 Financial Results (Unit: Billion yen) Q1 FYE/Mar. 2009 Q1 FYE/Mar. 2010 Rate of change Net Sales 77.8 77.5 0% Gross profit

More information

Financial Results for FYE/Mar Terumo Corporation. May 13, 2009

Financial Results for FYE/Mar Terumo Corporation. May 13, 2009 Financial Results for FYE/Mar 2009 Terumo Corporation May 13, 2009 1 Financial Results Net Sales Gross profit (%) S.G.A Expenses (%) Operating Income (%) Ordinary Income (%) Net Income Average exchange

More information

JP Morgan Conference. Jim Tobin Chief Executive Officer January 14, 2009

JP Morgan Conference. Jim Tobin Chief Executive Officer January 14, 2009 JP Morgan Conference Jim Tobin Chief Executive Officer January 14, 2009 Cautionary Statement for Purposes of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 This presentation

More information

Volcano Corporation (VOLC-NASDAQ)

Volcano Corporation (VOLC-NASDAQ) January 07, 2015 Volcano Corporation (VOLC-NASDAQ) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Date of Last Change 08/10/2007 Current Price (01/07/15) $17.95 Target Price $19.00 52-Week

More information

Citi's Global Health Care Conference. February 25, 2013

Citi's Global Health Care Conference. February 25, 2013 Citi's Global Health Care Conference February 25, 2013 1 Boston Scientific Citi Global Healthcare Conference, Feb 25, 2013. Refer to appendix to this presentation for certain regulatory and financial disclosures.

More information

Financial Results for the First Half of Fiscal Year Ending March 31, 2018 (FY2017)

Financial Results for the First Half of Fiscal Year Ending March 31, 2018 (FY2017) Financial Results for the First Half of Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer, Investor Relations, Corporate Communication Dept. Kazuaki Kitabatake November

More information

Boston Scientific Corporation

Boston Scientific Corporation March 06, 2015 Boston Scientific Corporation Current Recommendation Prior Recommendation Outperform Date of Last Change 10/16/2011 Current Price (03/05/15) $16.97 Target Price $18.00 NEUTRAL SUMMARY (BSX-NYSE)

More information

Financial Results for the First Quarter of Fiscal Year Ending March 31, 2019 (FY2018)

Financial Results for the First Quarter of Fiscal Year Ending March 31, 2019 (FY2018) Financial Results for the First Quarter of Fiscal Year Ending March 31, 2019 (FY2018) Terumo Corporation Managing Executive Officer, Kazuaki Kitabatake August 8, 2018 In Line with the Guidance on the Whole

More information

22 nd Annual Credit Suisse Healthcare Conference. November 12, nd Annual Credit Suisse Healthcare Conference November 12, 2013.

22 nd Annual Credit Suisse Healthcare Conference. November 12, nd Annual Credit Suisse Healthcare Conference November 12, 2013. 22 nd Annual Credit Suisse Healthcare Conference November 12, 2013 1 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of

More information

CONSOLIDATED FINANCIAL STATEMENTS

CONSOLIDATED FINANCIAL STATEMENTS FINANCIAL TABLE OF CONTENTS 2 Management s discussion and analysis of financial condition and results of operations 23 Consolidated statements of operations 2003 CONSOLIDATED FINANCIAL STATEMENTS 24 Consolidated

More information

Financial Results for the Fiscal Year Ended March 31, 2010 Outlook for the Fiscal Year Ending March 31, Terumo Corporation May 12, 2010

Financial Results for the Fiscal Year Ended March 31, 2010 Outlook for the Fiscal Year Ending March 31, Terumo Corporation May 12, 2010 Financial Results for the Fiscal Year Ended March 31, 2010 Outlook for the Fiscal Year Ending March 31, 2011 Terumo Corporation May 12, 2010 1 Net Sales Gross Profit SG&A Expenses Operating Income Ordinary

More information

Financial Results for the Fiscal Year Ended March 31, 2017 (FY2016) and Guidance for the Fiscal Year Ending March 31, 2018 (FY2017)

Financial Results for the Fiscal Year Ended March 31, 2017 (FY2016) and Guidance for the Fiscal Year Ending March 31, 2018 (FY2017) Financial Results for the Fiscal Year Ended March 31, 2017 (FY2016) and Guidance for the Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer, Investor Relations, Corporate

More information

Five-year Financial Summary (Consolidated)

Five-year Financial Summary (Consolidated) Five-year Financial Summary (Consolidated) Years ended March 31 Fiscal Year Millions of yen FY212 FY213 FY214 FY215 FY216 (Ended March 213) (Ended March 214) (Ended March 215) (Ended March 216) (Ended

More information

Teleflex Incorporated. First Quarter 2017 Earnings Conference Call

Teleflex Incorporated. First Quarter 2017 Earnings Conference Call Teleflex Incorporated First Quarter 2017 Earnings Conference Call 1 Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors

More information

investmnt Conference August 5, 2015 Susie Lisa, CFA Vice President, Investor Relations

investmnt Conference August 5, 2015 Susie Lisa, CFA Vice President, Investor Relations investmnt Conference August 5, 2015 Susie Lisa, CFA Vice President, Investor Relations 1 Safe harbor for forward-looking statements and Disclaimers This presentation contains forward-looking statements

More information

Driving Sustainable, Long-Term Growth

Driving Sustainable, Long-Term Growth Driving Sustainable, Long-Term Growth Rhonda Robb Chief Operating Officer July 31, 2018 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of

More information

Financial Results Briefing of FYE March 2019, Second Quarter

Financial Results Briefing of FYE March 2019, Second Quarter Financial Results Briefing of FYE March 2019, Second Quarter Presentation Material for Financial Results Briefing @ Nikkei Kayabacho Conference Room November 6, 2018 Japan Lifeline Co., Ltd. Today's Agenda

More information

Financial Results for the First Three Quarters of the Fiscal Year Ending March 31, 2016: Reference

Financial Results for the First Three Quarters of the Fiscal Year Ending March 31, 2016: Reference Financial Results for the First Three Quarters of the Fiscal Year Ending March 31, 2016: Reference Analysis of Business Performance 1. Overview of Financial Results for the First Three Quarters of the

More information

Credit Suisse Healthcare Conference. November 11, Dan Brennan, EVP & CFO

Credit Suisse Healthcare Conference. November 11, Dan Brennan, EVP & CFO Credit Suisse Healthcare Conference November 11, 2014 Dan Brennan, EVP & CFO 1 Safe harbor for forward-looking statements This presentation contains forward-looking statements within the meaning of Section

More information

Transparency Market Research

Transparency Market Research Transparency Market Research Angioplasty Balloons Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015-2023 Published Date 03-Aug-2015 86 Page Report Buy Now Request Sample

More information

Intellisight University of St. Thomas School of Law Minneapolis, MN. August 15, 2018

Intellisight University of St. Thomas School of Law Minneapolis, MN. August 15, 2018 Intellisight 2018 University of St. Thomas School of Law Minneapolis, MN August 15, 2018 Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning

More information

Revisions to Enhanced IncomeShield Plan

Revisions to Enhanced IncomeShield Plan Revisions to Enhanced IncomeShield Plan The revisions to your Enhanced IncomeShield Plan are summarised in the table below for your easy reference. They show the latest changes made to the Enhanced IncomeShield

More information

Bernstein s 34 th Annual Strategic Decisions Conference

Bernstein s 34 th Annual Strategic Decisions Conference Bernstein s 34 th Annual Strategic Decisions Conference Mike Mahoney Chairman and Chief Executive Officer Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements

More information

Financial Results of the 2nd Quarter for Fiscal Year ending June 2018

Financial Results of the 2nd Quarter for Fiscal Year ending June 2018 Financial Results of the 2nd Quarter for Fiscal Year ending June 2018 February 14, 2018 (Securities code: 7747 Second Section of the Tokyo Stock Exchange, Second Section of the Nagoya Stock Exchange) All

More information

Forward Looking Statements

Forward Looking Statements MAY 2016 [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical information, this presentation contains forward-looking statements with respect to

More information

Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer

Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer Kazuaki Kitabatake February 8, 2018 Maintained Good Momentum despite

More information

For personal use only

For personal use only FY16 Full Year Results 23 August 2016 Matt Muscio Chief Executive Officer Dean Taylor Chief Financial Officer Kristine James General Manager Corporate Development Agenda 1. Highlights 2. Financial Performance

More information

Community Clinical Data Exchange By the Numbers

Community Clinical Data Exchange By the Numbers Community Clinical Data Exchange By the Numbers Healthcare Information Technology 00 James Kalamas January 4, 00 WE ATTEMPTED TO QUANTIFY THE FINANCIAL VALUE OF CCDE Questions we set out to answer What

More information

The following are highlights of performance at each company during the fiscal year ended March 31, 2017.

The following are highlights of performance at each company during the fiscal year ended March 31, 2017. Financial Results for the Fiscal Year Ended March 31, 2017: Reference Analysis of Business Performance and Financial Position Analysis of Business Performance 1. Overview of Financial Results for the Fiscal

More information

3. 510(k) SUMMARY OCT

3. 510(k) SUMMARY OCT 3. 510(k) SUMMARY OCT 082008 This summary of510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. Applicant Information: 510(k)Number:

More information

Terumo Corporation IFRS Financial Results for the Fiscal Year Ended March 31, 2018

Terumo Corporation IFRS Financial Results for the Fiscal Year Ended March 31, 2018 Terumo Corporation IFRS Financial Results for the Fiscal Year Ended March 31, 2018 1 2 4. Consolidated Financial Statements 1 Consolidated Statements of Financial Position Assets Current assets As of April

More information

Transcatheter Cardiovascular Therapeutics 2018

Transcatheter Cardiovascular Therapeutics 2018 Transcatheter Cardiovascular Therapeutics 2018 Jeff Mirviss, SVP & President, Peripheral Interventions Kevin Ballinger, EVP & President, Interventional Cardiology Dr. Ian Meredith, EVP & Global Chief Medical

More information

Abbott Reports First-Quarter 2013 Results

Abbott Reports First-Quarter 2013 Results PRESS RELEASE Abbott Reports First-Quarter 2013 Results First-Quarter Ongoing EPS of $0.42 (GAAP EPS of $0.34) Company Confirms Full-Year 2013 EPS Guidance April 17, 2013 Abbott Park, Illinois (NYSE: ABT)

More information

Ended March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer

Ended March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer Financial ca Results for the Fiscal Year Ended March 31, 2018 (FY2017) Terumo Corporation Managing Executive Officer Kazuaki Kitabatake May 9, 2018 Achieved Highest Ever Revenue and All s FY16YTD FY17YTD

More information

Financial Results for the Fiscal Year Ended March 31, 2018: Reference. Analysis of Business Performance and Financial Position

Financial Results for the Fiscal Year Ended March 31, 2018: Reference. Analysis of Business Performance and Financial Position Financial Results for the Fiscal Year Ended March 31, 2018: Reference Analysis of Business Performance and Financial Position Analysis of Business Performance 1. Overview of Financial Results for the Fiscal

More information

Abbott Reports Second-Quarter 2018 Results

Abbott Reports Second-Quarter 2018 Results News Release Abbott Reports Second-Quarter 2018 Results Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40 Second-quarter organic sales growth of 8.0 percent

More information

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014 Marlborough, Mass. (October 22, 2014) -- Boston Scientific Corporation (NYSE: BSX) generated sales of

More information

Press Information. June 28, 2017

Press Information. June 28, 2017 Press Information June 28, 2017 Philips to acquire The Spectranetics Corporation to accelerate expansion in imageguided therapy devices to treat cardiac and peripheral vascular disease Highly complementary

More information

Hello, my name is Kazuaki Kitabatake. I will explain the 3 rd quarter results of the financial period ending March Please open to the second

Hello, my name is Kazuaki Kitabatake. I will explain the 3 rd quarter results of the financial period ending March Please open to the second Hello, my name is Kazuaki Kitabatake. I will explain the 3 rd quarter results of the financial period ending March 2015. Please open to the second slide. 1 First, highlights of the results. Similarly to

More information

BOSTON SCIENTIFIC CORPORATION

BOSTON SCIENTIFIC CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Í ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December

More information

Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017

Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017 Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017 Kevin Ballinger Executive Vice President and President, Interventional Cardiology Professor Ian Meredith, A.M. Executive Vice

More information

CHAPTER IV RESULTS AND DISCUSSION Efficiency of Working Capital Management

CHAPTER IV RESULTS AND DISCUSSION Efficiency of Working Capital Management CHAPTER IV RESULTS AND DISCUSSION This chapter is devoted to presentation and interpretation of the results obtained through the analysis of the data. The collected data were critically analyzed using

More information

Press Release February 28, 2018

Press Release February 28, 2018 ISRA VISION AG: First quarter 2017 / 2018 revenues grow by approx. +10 %, EBT by +11 % ISRA starts dynamically into the new financial year: Guidance again double-digit Revenues at 31.2 million euros, plus

More information

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013 Fourth Quarter Marks Third Consecutive Quarter of Improved Performance Natick, Mass. (February

More information

JP Morgan 27th Annual Healthcare Conference Angela F. Braly President & Chief Executive Officer January 12, 2009

JP Morgan 27th Annual Healthcare Conference Angela F. Braly President & Chief Executive Officer January 12, 2009 JP Morgan 27th Annual Healthcare Conference Angela F. Braly President & Chief Executive Officer January 12, 2009 Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995 The statements

More information

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE-MONTH PERIOD ENDED NOVEMBER 30, 2018

MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE-MONTH PERIOD ENDED NOVEMBER 30, 2018 MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE-MONTH PERIOD ENDED NOVEMBER 30, The following comments are intended to provide a review and analysis

More information

Q Highlights. February 1, 2018

Q Highlights. February 1, 2018 Q4 2017 Highlights February 1, 2018 Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within

More information

for FYE June, 2010 February 17, 2010 (Securities code : 7747

for FYE June, 2010 February 17, 2010 (Securities code : 7747 2nd Quarter Financial Results for FYE June, 21 February 17, 21 (Securities code : 7747 2nd section of the Tokyo Stock Exchange, 2nd section of the Nagoya Stock Exchange, JASDAQ) All Rights Reserved.Copyright

More information

Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceuticals Pricing Authority ORDER

Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceuticals Pricing Authority ORDER (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceuticals

More information

Q Highlights. October 26, 2017

Q Highlights. October 26, 2017 Q3 2017 Highlights October 26, 2017 Safe Harbor for forward-looking statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within

More information

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2007

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2007 BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2007 Natick, MA (April 23, 2007) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter

More information

Global Wealth Management Market: Size, Trends & Forecasts ( ) June 2018

Global Wealth Management Market: Size, Trends & Forecasts ( ) June 2018 Global Wealth Management Market: Size, Trends & Forecasts (2018-2022) June 2018 Global Wealth Management Market: Coverage Executive Summary and Scope Introduction/Market Overview Global Market Analysis

More information

2Q18 Earnings Conference Call. August 2, 2018

2Q18 Earnings Conference Call. August 2, 2018 2Q18 Earnings Conference Call August 2, 2018 Presentation of Financial Information & Forward-Looking Statements Historical financial and operating data in this presentation reflect the consolidated results

More information

Consolidated Financial Statements

Consolidated Financial Statements BOSTON SCIENTIFICAND AND SUBSIDIARIES Management s discussionand and analysis of of financial conditionand and results of of operations... 11 Management s report on on internal control over over financial

More information

Profile of a Global Leader

Profile of a Global Leader 2007 ANNUAL REPORT Profile of a Global Leader One of the world s largest medical device companies, with $8.357 billion in sales Sales in more than 100 countries Portfolio of approximately 13,000 products,

More information

Session 4B: Specialty Medical Billing Offices Challenges: Billing, Collections and Appeals:

Session 4B: Specialty Medical Billing Offices Challenges: Billing, Collections and Appeals: Session 4B: Specialty Medical Billing Offices Challenges: Billing, Collections and Appeals: Prepared and Presented by: Terry A. Fletcher BS, CPC, CCC, CEMC, SCP-CA, ACS-CA, CCS-P, CCS, CMSCS, CMC 1 Our

More information

Press Release December 15, 2016

Press Release December 15, 2016 ISRA VISION AG: 2015/2016 financial year Strong, double-digit growth for the full year: Revenues +15 %, EBT +15 % ISRA with high growth rates in the 2015 / 2016 financial year Revenues and EBT exceed forecast

More information

J.P. Morgan 34 th Annual Healthcare Conference January 12, 2016

J.P. Morgan 34 th Annual Healthcare Conference January 12, 2016 J.P. Morgan 34 th Annual Healthcare Conference January 12, 2016 Mike Mahoney President and Chief Executive Officer Safe harbor for forward-looking statements This presentation contains forward-looking

More information

BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter)

BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December

More information

AMENDMENT NUMBER la TO UNITED HEALTHCARE OF CALIFORNIA HOSPITAL SERVICES AGREEMENT (HMO, PPO, POS & SECURE HORIZONS) RECITALS

AMENDMENT NUMBER la TO UNITED HEALTHCARE OF CALIFORNIA HOSPITAL SERVICES AGREEMENT (HMO, PPO, POS & SECURE HORIZONS) RECITALS AMENDMENT NUMBER la TO UNITED HEALTHCARE OF CALIFORNIA HOSPITAL SERVICES AGREEMENT (HMO, PPO, POS & SECURE HORIZONS) this Amendment Number 14 to the Hospital Services Agreement (HMO, PPO, POS & Secure

More information

Fourth Quarter Fiscal Year 2017

Fourth Quarter Fiscal Year 2017 Fourth Quarter Fiscal Year 2017 October 25, 2017 J. Michael Bruff Vice President Investor Relations Mike.Bruff@Varian.com This presentation is intended exclusively for investors. It is not intended for

More information

HEALTH ECONOMICS AND REIMBURSEMENT

HEALTH ECONOMICS AND REIMBURSEMENT HEALTH ECONOMICS AND REIMBURSEMENT VASCULAR CY 2016 MEDICARE PHYSICIAN FEE SCHEDULE (PFS) UPDATE Abbott Vascular is pleased to provide you with this summary of the Medicare Physician Fee Schedule (PFS)

More information

The Global Healthcare Environment. Uwe Reinhardt, Princeton University & Hank Kucheman, Boston Scientific

The Global Healthcare Environment. Uwe Reinhardt, Princeton University & Hank Kucheman, Boston Scientific The Global Healthcare Environment Uwe Reinhardt, Princeton University & Hank Kucheman, Boston Scientific HEALTH CARE MARKETS ARE CHANGING: But you should be so lucky as to be in health care Uwe Reinhardt,

More information

Consolidated Financial Highlights for FY2014 (From April 1, 2014 to March 31, 2015)

Consolidated Financial Highlights for FY2014 (From April 1, 2014 to March 31, 2015) Consolidated Financial Highlights for FY2014 (From April 1, 2014 to March 31, 2015) 1. Consolidated Financial Results for FY2014 2. Forecast for FY2015 3. Revision of four-year mid-term business plan,

More information

BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017

BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017 FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017 Marlborough, Mass. (January 9, 2018) -- Boston Scientific Corporation

More information

Press Release December 15, 2017

Press Release December 15, 2017 ISRA VISION AG: 2016 / 2017 financial year Revenues and EBT +11 %, cash flow significantly stronger ISRA again matches full year guidance: Heading for the next revenue level with double-digit growth rates

More information

BOSTON SCIENTIFIC CORPORATION

BOSTON SCIENTIFIC CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December

More information

Science China Information Sciences

Science China Information Sciences A Simulator with Elastic Guidewire and Vascular for Minimally Invasive Vascular Surgery Xiaoran CHENG, Xiaoliang XIE, Guibin BIAN, Zengguang HOU, Shiqi LIU, and Zhanjie GAO The State Key Laboratory of

More information

Q Highlights. April 25, 2018

Q Highlights. April 25, 2018 2018 Highlights April 25, 2018 Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within the

More information

Indian Healthcare Industry

Indian Healthcare Industry Indian Healthcare Industry 2012 Synopsis Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Gyan Research and Analytics Pvt. Ltd. (Gyan). While

More information

Medical Alert Systems/Personal Emergency Response System (PERS) Market by Type (Landline PERS, Mobile PERS (MPERS), Standalone PERS), by End- User

Medical Alert Systems/Personal Emergency Response System (PERS) Market by Type (Landline PERS, Mobile PERS (MPERS), Standalone PERS), by End- User Medical Alert Systems/Personal Emergency Response System (PERS) Market by Type (Landline PERS, Mobile PERS (MPERS), Standalone PERS), by End- User (Home-Based, Senior Living Facilities, and Assisted Living

More information

PRIMARY INSURANCE Subscriber s/guarantor s

PRIMARY INSURANCE Subscriber s/guarantor s For proper insurance billing. If left blank, billing will be returned for completion. PATIENT INFORMATION Name: Last Name First Name M.I. Soc.Sec.# Street Address: City: State: Zip: Phone: Other Number(s):

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Investor Presentation May 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive

More information

Net Exports and Capital Flows: Linking Financial and Goods Markets

Net Exports and Capital Flows: Linking Financial and Goods Markets ACTIVITY 7-5 Net Exports and Capital Flows: Linking Financial and Goods Markets The term capital flow refers to the movement of financial capital (money) between economies. Capital inflows consist of foreign

More information

Toshihiko Osada General Manager, Strategic Planning Department. Corporate Strategy. Terumo Corporation Dec 12, 2016

Toshihiko Osada General Manager, Strategic Planning Department. Corporate Strategy. Terumo Corporation Dec 12, 2016 2 Toshihiko Osada General Manager, Strategic Planning Department Corporate Strategy Outlook: Medtech Industry Global medtech market: Forecast to grow at a CAGR of 5-6% for the next 10 years, with market

More information

Steve Martens VP Investor Relations FY13 Q3

Steve Martens VP Investor Relations FY13 Q3 Steve Martens VP Investor Relations steve.martens@molex.com FY13 Q3 Forward-Looking Statement Statements in this presentation that are not historical are forward-looking and are subject to various risks

More information

PROFESSIONAL CLAIMS CODE EDITING AND DOCUMENTATION REQUIREMENTS GUIDELINES Updated April 22, 2009

PROFESSIONAL CLAIMS CODE EDITING AND DOCUMENTATION REQUIREMENTS GUIDELINES Updated April 22, 2009 PROFESSIONAL CLAIMS CODE EDITING AND DOCUMENTATION REQUIREMENTS GUIDELINES Updated April 22, 2009 Professional outpatient services are identified by submitting Current Procedure Terminology (CPT ) codes

More information

1st Quarter Financial Results for FYE June, 2015

1st Quarter Financial Results for FYE June, 2015 1st Quarter Financial Results for FYE June, 2015 November 14, 2014 (Securities code : 7747 2nd section of the Tokyo Stock Exchange, 2nd section of the Nagoya Stock Exchange) All Rights Reserved.Copyright

More information

Financial Results of the 1 st Quarter for Fiscal Year ending June 2019

Financial Results of the 1 st Quarter for Fiscal Year ending June 2019 Financial Results of the 1 st Quarter for Fiscal Year ending June 2019 November 13, 2018 (Securities code: 7747 First Section of the Tokyo Stock Exchange, First Section of the Nagoya Stock Exchange) All

More information

September 14, Dear Administrator Verma:

September 14, Dear Administrator Verma: September 14, 2018 Seema Verma Administrator Centers for Medicare and Medicaid Services Dept. of Health and Human Services Attention: CMS-1695-P P.O. Box 8013 Baltimore, MD 21244-1850 Re: CMS-1695-P; Medicare

More information

June 2015 NASDAQ: RDNT

June 2015 NASDAQ: RDNT June 2015 NASDAQ: RDNT Safe Harbor This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning

More information

QT VASCULAR S BOARD OF DIRECTORS PROVIDES UPDATES ON LITIGATION CASE

QT VASCULAR S BOARD OF DIRECTORS PROVIDES UPDATES ON LITIGATION CASE MEDIA RELEASE QT VASCULAR S BOARD OF DIRECTORS PROVIDES UPDATES ON LITIGATION CASE Highlights: CEO reaffirms that Board s position on the information regarding the patent claim as stated in the IPO Offer

More information

ABBOTT PARK, Ill., July 20, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2016.

ABBOTT PARK, Ill., July 20, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2016. Abbott Reports Second-Quarter 2016 Results - SECOND-QUARTER REPORTED SALES GROWTH OF 3.2 PERCENT; OPERATIONAL SALES GROWTH OF 6.4 PERCENT - SECOND-QUARTER GAAP EPS FROM CONTINUING OPERATIONS OF $0.40;

More information

Price Disparity of Medical Devices in Japan and Overseas

Price Disparity of Medical Devices in Japan and Overseas Experience & Review Price Disparity of Medical Devices in Japan and Overseas Identifying the Issues and Finding the Solution Yoshio Uetsuka1 and Saichi Hosoda2 1 Department of Health Services and Hospital

More information

JP Morgan Healthcare Conference January 13, 2016

JP Morgan Healthcare Conference January 13, 2016 JP Morgan Healthcare Conference January 13, 2016 FORWARD-LOOKING STATEMENTS Certain statements and information in this presentation may be deemed to be forward-looking statements within the meaning of

More information

Q Highlights. July 25, 2018

Q Highlights. July 25, 2018 Q2 2018 Highlights July 25, 2018 Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within

More information

GENESIS HEALTHCARE SYSTEM

GENESIS HEALTHCARE SYSTEM GENESIS HEALTHCARE SYSTEM Quarterly Financial Disclosure Statement As of and for the Six Months Ended June 30, 2013 PLEASE NOTE THAT THIS DOCUMENT INCLUDES MANAGEMENT S DISCUSSION AND ANALSYIS, AS WELL

More information

Portfolio CORDIS. FRONTRUNNER XP CTO Catheter. AQUATRACK Hydrophilic Nitinol Guidewire. OUTBACK TM Elite Re-Entry Catheter

Portfolio CORDIS. FRONTRUNNER XP CTO Catheter. AQUATRACK Hydrophilic Nitinol Guidewire. OUTBACK TM Elite Re-Entry Catheter Elite Re-Entry Catheter FRONTRUNNER XP CTO Catheter AQUATRACK Hydrophilic Nitinol Guidewire NO CROSS GUARANTEE At cordis, we re committed to providing the most comprehensive offering of reliable and powerful

More information

The IDEXX Opportunity

The IDEXX Opportunity The IDEXX Opportunity 1 2018 IDEXX Laboratories, Inc. All rights reserved. Brian McKeon, Executive Vice President and CFO Bank of America Merrill Lynch Global Healthcare Conference London I September 12,

More information

The role of data analytics in present and future claims cost containment

The role of data analytics in present and future claims cost containment Image: loveguli / Getty Images The role of data analytics in present and future claims cost containment Dr. Andreas Bayerstadler Senior Consultant Business Analytics Dubai, 12 th September 2018 Wearables

More information

Intuitive Surgical Announces Third Quarter Earnings

Intuitive Surgical Announces Third Quarter Earnings Intuitive Surgical Announces Third Quarter Earnings October 18, SUNNYVALE, Calif., Oct. 18, (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. ( Intuitive ) (Nasdaq: ISRG), a global technology leader in roboticassisted,

More information

ÖSSUR COMPANY PROFILE. Sveinn Sölvason, CFO

ÖSSUR COMPANY PROFILE. Sveinn Sölvason, CFO ÖSSUR COMPANY PROFILE Sveinn Sölvason, CFO Arion Banki 8 April 2015 FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements, which reflect the Management s current views with respect

More information

POWERed for Growth Annual Report

POWERed for Growth Annual Report POWERed for Growth 2010 Annual Report 2010 Sales by Product Category Our sales in 2010 represented a large, stable and diversified revenue base. We are developing profitable opportunities in these and

More information

Bin Yuan Capital First Quarter 2017

Bin Yuan Capital First Quarter 2017 Bin Yuan Capital First Quarter 2017 Market Review The Chinese stocks consolidated in March after increasing for two consecutive months in January and February. During the first quarter, the Shanghai Composite

More information

FFR Market. FFR Cornerstone for Opsens growth. Opsens - Creating value. For Your Information

FFR Market. FFR Cornerstone for Opsens growth. Opsens - Creating value. For Your Information ANNUAL REPORT 2017 Opsens focuses on the measure of Fractional Flow Reserve ( FFR ) in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving

More information

Abbott Reports First-Quarter 2019 Results

Abbott Reports First-Quarter 2019 Results News Release Abbott Reports First-Quarter 2019 Results Sales and EPS growth exceed guidance; projects strong full-year outlook Long-term growth drivers including FreeStyle Libre, MitraClip and Alinity

More information